Want to see MRKR full AI Analyst Report?
Top Page
Marker Therapeutics
(NASDAQ:MRKR)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.50
▲(22.95% Upside)
Action:Reiterated
Date:08/25/26
MRKR’s score is held down primarily by weak financial performance—declining revenue, persistent losses, and ongoing cash burn—despite the benefit of having no debt. Technicals are comparatively better, with price trading above major moving averages, but valuation support is limited given negative earnings and no dividend yield data.
Positive Factors
Debt-Free Balance Sheet
A debt-free balance sheet reduces refinancing risk, interest obligations, and exposure to lender constraints. This gives Marker greater flexibility to prioritize clinical development and limits the financial pressure that leverage could add.
Negative Factors
Declining Revenue
Declining revenue and the very small revenue base indicate limited commercial traction or inconsistent non-product funding. This weakens internal financing capacity and leaves Marker dependent on clinical progress, collaborations, or external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
A debt-free balance sheet reduces refinancing risk, interest obligations, and exposure to lender constraints. This gives Marker greater flexibility to prioritize clinical development and limits the financial pressure that leverage could add.
Read all positive factors
Marker Therapeutics (MRKR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.01M
Dividend YieldN/A
Average Volume (3M)56.86K
Price to Earnings (P/E)―
Beta (1Y)1.76
Revenue Growth-56.64%
EPS Growth64.88%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding16,673,126
10 Day Avg. Volume37,502
30 Day Avg. Volume56,863
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.36
Price to Sales (P/S)0.00
P/FCF Ratio-1.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside637.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$4.18M
Marker Therapeutics Business Overview & Revenue Model
Company Description
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both ...
How the Company Makes Money
Marker Therapeutics does not operate as a traditional commercial-stage company with recurring product sales; its business model is primarily that of a development-stage biotech focused on advancing drug candidates through clinical development. As ...
Marker Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.23M | 0.00 | 6.59M | 3.31M | 3.51M | 1.24M |
| Gross Profit | -3.96M | 0.00 | -6.88M | -7.11M | -8.45M | -1.92M |
| EBITDA | -8.72M | -12.44M | -10.68M | -11.25M | -16.99M | -38.72M |
| Net Income | -8.71M | -12.16M | -10.73M | -8.24M | -29.93M | -41.88M |
Balance Sheet | ||||||
| Total Assets | 14.59M | 19.07M | 22.02M | 17.13M | 34.42M | 68.14M |
| Cash, Cash Equivalents and Short-Term Investments | 11.33M | 16.07M | 19.19M | 15.11M | 11.78M | 42.35M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 7.62M | 11.87M |
| Total Liabilities | 2.42M | 2.27M | 3.46M | 3.07M | 14.82M | 24.15M |
| Stockholders Equity | 12.17M | 16.80M | 18.56M | 14.05M | 19.60M | 43.99M |
Cash Flow | ||||||
| Free Cash Flow | -9.76M | -12.01M | -10.91M | -16.44M | -26.97M | -30.41M |
| Operating Cash Flow | -9.76M | -12.01M | -10.91M | -16.44M | -26.97M | -27.28M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 18.66M | -4.95M | -3.13M |
| Financing Cash Flow | 9.86M | 9.86M | 14.99M | 1.11M | 202.13K | 52.56M |
Marker Therapeutics Technical Analysis
Positive
1.22
Price Trends
1.31
Positive
1.40
Positive
1.42
Positive
Market Momentum
0.03
Negative
67.85
Neutral
87.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRKR, the sentiment is Positive. The current price of 1.22 is above the 20-day moving average (MA) of 1.20, below the 50-day MA of 1.31, and below the 200-day MA of 1.42, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 67.85 is Neutral, neither overbought nor oversold. The STOCH value of 87.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRKR.
Marker Therapeutics Risk Analysis
Marker Therapeutics disclosed 55 risk factors in its most recent earnings report. Marker Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Marker Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $25.01M | -3.13 | -73.29% | ― | -56.64% | 64.88% | |
47 Neutral | $70.54M | -2.47 | -53.86% | ― | -20.00% | 75.26% | |
46 Neutral | $4.12M | -0.51 | -131.35% | ― | -50.79% | -180.59% | |
46 Neutral | $22.12M | -1.78 | -109.94% | ― | ― | 91.38% | |
44 Neutral | $22.39M | -2.85 | -92.03% | ― | -100.00% | -55.90% | |
39 Underperform | $11.87M | -0.04 | 3114.17% | ― | ― | 85.06% |
* Healthcare Sector Average
MRKR
Marker Therapeutics
1.52
0.52
52.00%
IBIO
Ibio
1.47
0.68
86.79%
MBRX
Moleculin Biotech
0.61
-13.03
-95.52%
ABVC
ABVC BioPharma
0.80
-2.18
-73.19%
ADXN
Addex Therapeutics
3.90
-3.93
-50.16%
ALLR
Allarity Therapeutics
1.33
-0.10
-6.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.